SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

The FDA issued a Complete Response Letter for Summits ivonescimab application in EGFR-mutated lung cancer, citing the lack of statistically significant overall-survival benefit despite a strong progression-free-survival result; the decision has prompted bearish selling and debate over a possible appeal. Some traders view the setback as limited to this indication and point to future HARMONi-3 data and the broader pipeline, while others question the near-term outlook.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol Myers quarterly results are drawing attention after revenue and adjusted earnings topped expectations and the company raised its revenue outlook, while lowering its EPS outlook partly because of licensing-related charges. Traders are weighing the strong results and pipeline progress against the weaker EPS guidance, patent-cliff concerns, and mixed technical signals.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharmas anticipated Phase 3 APPROACH topline results for HLP003 in major depressive disorder dominate discussion, with traders treating the readout as a binary catalyst. Optimists point to its adjunctive design and potential for shorter clinic sessions, while skeptics flag the risk that Phase 2 efficacy may not replicate, alongside dilution and competitive concerns.

L3Harris Technologies, Inc. engages in the provision of defense and commercial technologies across the air, land, sea, space, and cyber domains. It operates through the following segments: Communication Systems, Integrated Mission Systems, Space and Airborne Systems, and Aerojet Rocketdyne. The Communication Systems segment enables warfighters across all domains with solutions critical to mission success even in the most contested environments. The Integrated Mission Systems segment focuses on the differentiated mission capabilities and prime systems integration for the air, land, and sea domains. The Space and Airborne Systems segment provides full mission solutions as a prime and subsystem integrator in the space, airborne, and cyber domains. The Aerojet Rocketdyne segment includes propulsion, power and armament products and systems to U.S. government, including the DoD, National Aeronautics and Space Administration (“NASA”) and major aerospace and defense prime contractors. The company was founded in 1890 and is headquartered in Melbourne, FL.

L3Harris Technologies Inc

L3Harris is drawing attention over a nationwide FAA communications outage that officials and reports have linked to its network, with investigators still determining whether equipment or installation problems were responsible. Traders are debating potential liability and contract fallout versus claims the company is being scapegoated, while some view the selloff as a buying opportunity.

Stellar (XLM) is a cryptocurrency launched in 2014. Stellar has a current supply of 50,001,786,837.39707 with 35,407,563,191.01116 in circulation. The last known price of Stellar is 0.13466341 USD and is down -7.69 over the last 24 hours. It is currently trading on 849 active market(s) with $286,159,144.84 traded over the last 24 hours. More information can be found at https://www.stellar.org.

Stellar Lumens

XLM is drawing attention amid persistent selling and volatile, weak price action, with traders divided between buying the dip and warning of further declines. Bulls point to Stellars DTCC and real-world-asset tokenization prospects, while skeptics argue that institutional activity has yet to translate into stronger token performance.

Autonomi (ANT) is a cryptocurrency launched in 2025and operates on the Arbitrum platform. Autonomi has a current supply of 1,200,000,000 with 346,331,579 in circulation. The last known price of Autonomi is 0.03106712 USD and is down -0.55 over the last 24 hours. It is currently trading on 15 active market(s) with $122,300.99 traded over the last 24 hours. More information can be found at https://autonomi.com.

Aragon

Attention is largely driven by ticker confusion with Anthropics widely discussed IPO, with many posts using Aragons $ANT.X tag for the AI company. Aragon-specific comments instead focus on the projects dissolution, the completed token redemption, and concerns about exchange delisting; no single new market catalyst for the crypto is established.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTechs positive Phase 2 results for its HER2-targeted drug trastuzumab pamirtecan in recurrent endometrial cancer are drawing attention to its oncology pipeline. Traders are reacting optimistically to the clinical progress, while broader concerns about execution and leadership remain part of the debate.

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

Delcaths quarterly results beat expectations and came with a higher 2026 revenue outlook, driving attention to HEPZATOs commercial growth and expanding hospital-site adoption. Traders largely welcomed the update, while some cautioned that the sharp rally has left the chart extended and are watching whether treatment uptake and cash conversion sustain momentum.

Uranium Energy Corp. engages in the provision of uranium and titanium mining and related activities, including exploration, pre-extraction, extraction, and processing of uranium concentrates, and titanium minerals. It operates through the following geographical segments: Wyoming, Texas, Saskatchewan, and Others. The company was founded by Alan P. Lindsay and Amir Adnani on May 16, 2003 and is headquartered in Corpus Christi, TX.

Uranium Energy Corp

UEC is drawing attention amid a sharp selloff and debate over its latest results: bearish traders point to losses, inconsistent revenue and softer uranium prices, while bulls argue its production ramp, cash-rich balance sheet and long-term nuclear-fuel demand support the investment case. The discussion is split between continued downside concerns and dip-buying around the uranium sectors longer-term prospects.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell is caught in a broader AI-hardware selloff, which traders link to Nvidia-related leadership turmoil and worries that data-center spending and server demand may weaken. Bulls point to Dells backlog and ongoing demand, while bears focus on thin margins, customer financing and the risk of capex slowing; speculation about China-related exposure also appears but is disputed.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
